文献速递精神分裂症与精神病性障碍

胆碱能调节剂治疗精神分裂症的疗效与安全性:随机对照试验荟萃分析

Efficacy and safety of cholinergic modulators in patients with schizophrenia: meta-analysis of randomised controlled trials.
PubMed 文献 · Br J Psychiatry · 2025-05-02

该荟萃分析纳入30项随机对照试验共3128例精神分裂症患者,评估胆碱能调节剂作为单药或辅助治疗的疗效与安全性。结果显示胆碱能调节剂未显著改善PANSS总分,但显著改善阴性症状;毒蕈碱激动剂改善总分、阳性症状、阴性症状及CGI-S,烟碱激动剂改善阴性症状及CGI-S;实验组不良事件发生率与安慰剂无显著差异。

要点

  • 胆碱能调节剂显著改善精神分裂症阴性症状(SMD=-0.42),对PANSS总分无显著改善。
  • 毒蕈碱激动剂改善PANSS总分、阳性及阴性症状和CGI-S,烟碱激动剂改善阴性症状和CGI-S。
  • 实验组不良事件风险与安慰剂无显著差异(OR=1.21,95%CI 0.94-1.56)。

核心结论

  • 胆碱能调节剂显著改善精神分裂症阴性症状,毒蕈碱激动剂在多个症状域及严重程度上均显示改善,且不良事件与安慰剂无显著差异。

研究设计与样本

  • 荟萃分析纳入30项随机对照试验,共3128例精神分裂症患者,评估胆碱能调节剂作为单药或辅助治疗。
  • 数据来源包括MEDLINE/PubMed、Embase、Scopus、Cochrane数据库及注册库,采用随机效应模型估计效应量,遵循PRISMA指南。

主要发现

  • 胆碱能调节剂未显著改善PANSS总分(SMD=-0.38;95%CI -0.93, 0.18;中等确定性证据)。
  • 胆碱能调节剂显著改善阴性症状评分(SMD=-0.42;95%CI -0.59, -0.25;中等确定性证据)。
  • 毒蕈碱激动剂改善PANSS总分(SMD=-0.57;95%CI -0.72, -0.42)、阳性症状(SMD=-0.58;95%CI -0.73, -0.43)、阴性症状(SMD=-0.40;95%CI -0.59, -0.21)及CGI-S(SMD=-0.48;95%CI -0.65, -0.31)。
  • 烟碱激动剂改善阴性症状(SMD=-0.28;95%CI -0.47, -0.09)及CGI-S(SMD=-1.31;95%CI -2.38, -0.24)。
  • 实验组不良事件发生率较高(OR=1.21;95%CI 0.94, 1.56)。

关键数值与推荐

  • 胆碱能调节剂改善阴性症状的SMD为-0.42(95%CI -0.59, -0.25),证据确定性为中等。
  • 毒蕈碱激动剂改善PANSS总分的SMD为-0.57(95%CI -0.72, -0.42),改善CGI-S的SMD为-0.48(95%CI -0.65, -0.31)。
  • 烟碱激动剂改善CGI-S的SMD为-1.31(95%CI -2.38, -0.24)。
  • 实验组不良事件OR为1.21(95%CI 0.94, 1.56)。

临床怎么用

  • 对于精神分裂症阴性症状突出的患者,可考虑胆碱能调节剂作为辅助治疗,尤其是毒蕈碱激动剂。
  • 使用胆碱能调节剂时需监测不良事件,尽管当前证据未显示显著差异。

局限性

  • 多数研究为低偏倚风险,但证据质量范围从极低到中等。
  • 胆碱能调节剂对PANSS总分的改善未达统计学显著性,证据确定性为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One-third of schizophrenia patients show a lack of response to conventional antipsychotic drugs because of adverse effects and limited efficacy. Emerging treatments target muscarinic and nicotinic receptors, leveraging cholinergic dysfunction implicated in the pathophysiology of schizophrenia. AIMS: To evaluate the efficacy and safety of cholinergic modulators in schizophrenia. METHODS: Reviewers extracted data from clinical trials sourced via MEDLINE/PubMed, Embase, Scopus, Cochrane databases and registries. Quality was assessed with a risk-of-bias tool and a random-effects model estimated effect size. Subgroup analysis, meta-regression and sensitivity analysis were performed as needed, adhering to PRISMA guidelines. RESULTS: A total of 30 randomised controlled trials (3128 participants) tested cholinergic modulators as monotherapy or adjunct therapy. They did not significantly improve Positive and Negative Syndrome Scale (PANSS) total scores (standardised mean difference (SMD): -0.38; 95% CI: -0.93, 0.18; moderate certainty evidence) but did improve negative symptom scores (SMD: -0.42; 95% CI: -0.59, -0.25; moderate certainty evidence). Muscarinic agonists improved total (SMD: -0.57; 95% CI: -0.72, -0.42), positive (SMD: -0.58; 95% CI: -0.73, -0.43) and negative symptoms of PANSS (SMD: -0.40; 95% CI: -0.59, -0.21), as well as Clinical Global Impression-severity (CGI-S) (SMD: -0.48; 95% CI: -0.65, -0.31). Nicotinic agonists aided negative symptoms (SMD: -0.28; 95% CI: -0.47, -0.09) and CGI-S (SMD: -1.31; 95% CI: -2.38, -0.24). Adverse events were higher (odds ratio: 1.21; 95% CI: 0.94, 1.56) in the experimental group. CONCLUSION: Cholinergic modulators significantly improve negative symptoms, with muscarinic agonists showing improvement across symptom domains and severity, without notable differences in adverse effects from placebo. Most studies were at low bias risk; evidence quality ranged from very low to moderate.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Shaju A, Mishra A, Mohapatra D, et al. Efficacy and safety of cholinergic modulators in patients with schizophrenia: meta-analysis of randomised controlled trials. Br J Psychiatry. 2025. PMID: 40314158. doi:10.1192/bjp.2025.44

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。